giovedì 23 marzo 2017

Coltivare cannabis per rilanciare lo sviluppo economico italiano

Il 2015 è stato l' anno di Expo a Milano. E' stato presentato un interessante progetto di sviluppo dell'agricoltura sostenibile, ad impatto 0, utilizzando risorse rinnovabili, evitando lo sfruttamento del suolo: Skyland.

Pensavano di costruirlo a Milano per Expo, così come era stata costruita la Torre Eiffel per l' esposizione universale a Parigi del 1889. Ragioni economiche hanno, ovviamente, evitato la costruzione di un'opera ingegnieristica che potrebbe rilanciare l'economia italiana. Perchè? Perchè la costruzione di grattacieli di 30 piani e la vendita di questi "innovativi" impianti, genererebbe un indotto del quale potrebbe avvantaggiarsi tutta l'economia italiana.

Aimè l'economia oggi va male e sognare che l'Italia possa tornare economicamente la potenza che è stata durante gli anni 50 sembrerebbe un sogno. 

Se non fosse che proprio la coltivazione della cannabis potrebbe permettere la realizzazione a costo zero di Skyland e lanciare una nuova politica industriale basata sul lancio di una impiantistica agroindustriale per paesi in via di sviluppo. Vendere tecnologia in cambio di quello che è più utile per la nostra nazione.

Ma come sarebbe possibile tutto questo? 

Skyland prevede la realizzazione di un'area coltivabile di 100.000 mq. La destinazione di 33.000 mq a coltivazione di cannabis medica potrebbe generare circa 400 milioni di euro l'anno e ricavi stimabili attorno ai 300 milioni annui. Con questi numeri la costruzione di un grattacielo "verde" non solo risulta economicamente sostenibile, ma i ritorni dall'investimento nell'infrastruttura sarebbe certi e veloci. Resterebbero altri 67.000 mq per la coltivazione a km zero di vegetali, la realizzazione di spazi per la vendita al dettagli a km zero di prodotti biologici senza l'uso di pesticidi (dati dalla coltivazione indoor) dal produttore al consumatore con risparmi notevoli per quest'ultimo che eviterebbe la GDO. I raccolti sarebbero certi e non sottomessi alle bizze del tempo garantendo prezzi stabili per i consumatori.

L'indotto generato da un piano industriale nazionale finalizzato al lancio di questa nuova tecnologia potrebbe dare respiro e nuova linfa a settori che vanno dalla edilizia (per la realizzazione della struttura), all'elettronica, all'idraulica, all'energetica, solo per citarne alcuni.

Ma oggi tutto è fermo. La politica sta frenando lo sviluppo italiano. La cannabis è coltivabile solo sulla carta, tramite una autorizzazione ministeriale che, se chiesta, non verrà mai concessa. 

Una minoranza ottusa impedisce il rilancio italiano, credendo ancora che parlare di cannabis significhi parlare di "droga" e pensando ancora che questo gli porterà voti.

E' un peccato che l'italia non abbia la possibilità di realizzare una politica industriale nazionale e che, ancora oggi, parlare di cannabis si riduca ad una "allucinazione" proibizionista.

sabato 18 marzo 2017

Cannabis Science Inc (OTCMKTS:CBIS) Gets Delivery Announcements For Initial Greenhouse Orders

By Elizabeth Jackson / in Marijuana / on Tuesday, 14 Mar 2017 03:06 AM 

Cannabis Science Inc (OTCMKTS:CBIS) a U.S. firm specializing in the advancement of cannabis-based drugs announced the anticipated delivery of its first pre-designed greenhouses with tracking and reporting protocols available for delivery this week for California and Nevada operations.
Time to enhance efficiencies

Dr. Allen Herman, the CMO, said that having control over Cannabis Science supply chain will increase efficiencies, counting the cost and time required to have processed items readily available for development into formulations. Observational studies will be soon launched for specific cannabinoid combinations for certain critical ailments. The need is to grow a variety of cannabinoid combinations for testing and formulations.

Moreover, each formulation will target a certain critical ailment and work using a specific delivery mode. It will sport the potency to achieve maximum positive results in subject usage. The company has received multiple emails inquiring about the clinical research timing and the availability of cure options. These inquiries are about the pain management, peripheral neuropathies, COPD and cancer.

All inquiries are entered into in-house database and they will be responding to all as each targeted observational trial officially begins. The trials will comprise some of the more than 500 cannabinoids isolated and noted from Cannabis sativa. These cannabinoids come under the chemical class of terpenophenolics, and 85 out of these 500 cannabinoids have been uniquely recognized in cannabis.

Common crop cannabinoids include tetrahydrocannabinol, cannabidiol, cannabigerol, cannabichromene and cannabinol. The THC pharmacology has been widely assessed, and it is regarded as the prime psychoactive constituent of cannabis. Their in-house database will mark the foundation of PCOR for a variety of critical disorders.

Later, Cannabis Science will develop protocols for their international consortium of South African, European and United States universities and research institutions. It will support research conventions for animal studies and clinical trials for numerous serious clinical ailments concurrently.

lunedì 13 marzo 2017

Dr. Stuart Titus, CEO Of Medical Marijuana Inc., Talks About Running "A Company Of Firsts"

By Nick Hilden | Mar 7, 2017 | C-Suite, Cannabis Investing

Dr. Stuart Titus is the CEO at Medical Marijuana Inc. (OTC: MJNA, OTCMKTS: MJNA), which has been pushing the boundaries of the medicinal space for nearly a decade. The company produces a range of hemp CBD oil products.

For starters, what makes your company different from others in the cannabis space?
We are a company of firsts – we were the first public company in the space in March 2009, the first to develop a natural botanical hemp-based CBD nutritional supplement, the first to legalize a cannabis-based product into a Latin American country (Brazil, April 2014), the first to legalize a cannabis based product into Mexico, and the first to develop a cannabis based product that qualifies for World Anti-Doping Standards.

How did you get into the cannabis space?
I entered this space via my physiotherapy career – I saw numerous athletes using cannabis to relieve pain, control inflammation, or just to help “get into the zone”. So I started attending medical cannabis symposiums to see if there was any real science behind this, and my eyes were opened to a new world of cannabis-based therapeutics.

Walk us through a normal day.
It starts with meetings with sales associates followed by meetings with management on product innovation, formulation. Next, media requests and developing presentation materials, then reading up on the latest clinical studies. From there I check the performance of our stock, our pharma partner’s stock, and other stocks in the space. Then I look at our international business, look at methods of streamlining out existing business, and work with our main investors and financiers to develop improved laboratory operations. This often involves discussing product formulations with existing and potentially new formulators. Some days involve participating in board meetings, preparing quarterly financial reports, speaking on company conference calls and representatives’ podcasts, and speaking with doctors interested in CBD.

What has been your biggest lesson about working in cannabis, and in business in general?

When it comes to business in general, extraordinary patience can be a virtue. As far as cannabis goes – never take anything for granted

What do you see as your biggest opportunity?
To revolutionize neurological medicine, educate doctors as well as lay people about the therapeutic benefits of cannabis, change the way we think about cannabis, develop a national dialogue regarding cannabis, and – on a personal note – to retire someday.

Do you have any thoughts or concerns about Sean Spicer’s statements indicating the Administration’s intention to crack down on recreational cannabis?
None at all, I consider it a smokescreen to distract from other happenings.

What sets you apart to make you a potential leader in cannabis?
My in-depth knowledge of the science and research, and that we are actually doing it. We currently have two divisions in pharma development, and are the first to do so.

What is the most frustrating aspect of the cannabis industry today?
Everyone wants to make a quick nickel instead of a slow dollar

What would you say to those who are considering investing in your company?
We are a diversified portfolio company with 4 divisions in nutraceutical sales. We have two investment companies in pharmaceutical development. The trends toward legalization of cannabis are unmistakable. The international acceptance of cannabis and CBD products is growing. The ability to grow hemp here in the US is a compelling business opportunity. With legalization, our company plans to enter into the THC space. We would potentially have multiple sources of revenue in the future. There is excellent investor interest in the space at this time.

What are the biggest challenges of being a publicly offered cannabis company?
The reporting requirements are staggering in terms of manpower, hours, and expense. It’s also a challenge to separate inside information from public information.

What advice would you give to anyone looking to get into the cannabis space?
This is potentially one of the greatest growth industries in America. The magnitude and impact of this could be bigger than anything previously seen. We can move toward a sustainable, renewable economy with jobs for all.

What are your biggest tips for branding cannabis?
Separate yourself from the crowd through innovation.

Do you see any big changes coming in the future of cannabis?
There will be more cannabinoids, and more acceptance of botanical cannabis. The US will follow Canada in allowing licensed producers. The US will also follow Canada in terms of full recreational legalization.

Do you consume cannabis? And if so, what's your favorite way to consume?
Yes, at least 50 mg of CBD daily. In the morning I take RSHO Blue. Through the day, Revive Pro. At night, RSHO Green. And I apply a topical salve daily. Occasionally I’ll enjoy a THC edible.

martedì 7 marzo 2017

Cannabis Science Inc (OTCMKTS:CBIS) To Attend Global Health Catalyst Summit At Harvard Medical School

Cannabis Science Inc (OTCMKTS:CBIS) has announced that it would be represented by its CEO, Raymond C. Dabney, at the Global Health Catalyst Summit, due to be held at the Harvard Medical School, on April 28-30, 2017. The company stated that Mr. Dabney would be a keynote speaker, at the summit and would also be a part of the panel. Added to this, the CMO of CBIS, Allen Herman, has also been invited to the summit, to co-chair a special session at the summit.
It should be noted here that Cannabis Science and the Harvard Medical School have a close working relationship. Mr. Dabney and Mr. Herman, have previously visited the school and delivered presentations about the rapidly developing medical cannabis industry. Further details from the company have revealed that Mr. Dabney has been asked to be a keynote speaker and panelist for a special session on “Cannabis Science Versus Cancer and Other Malignancies.”
In addition to this, Mr. Dabney plans to use the summit as a platform for providing an overview of the company, its drug development programs and the ongoing collaborative research agreement between the school and the company. CBIS is viewing the summit as an opportunity to discuss some of its cutting edge research, with the top minds in the medicinal industry. Moreover, the company also plans to establish partnerships, with institutions, present at the conference.
Mr. Dabney expressed his excitement about the potential partnership with the Dana-Farber Research Center, at Harvard Medical School. He claimed that his meeting with Wilfred Ngwa, the director of global health catalyst, at the center, had led to the immediate realization of potential synergies, in cancer research. The two had first met in September 2016, at the annual Constituency For Africa summit and went on to develop a research partnership in later months.
Cannabis Science Inc (OTCMKTS:CBIS) completed the March 3 trading session with a gain of 3.87% in terms of its share value, to close at $0.094 per share. The stock had a trade volume of 34.72 million, during the session.

martedì 21 febbraio 2017

Ministers endorse bill to export medicinal cannabis

Ministers on Sunday endorse a draft bill to legalize export of cannabis for approved medical use, Justice Minister Ayelet Shaked’s office says, without elaborating.

Adoption by the Ministerial Committee on Legislation, which meets outside the full cabinet, means that the draft will now move forward as a government bill.

Shaked’s office says a scheduled debate on decriminalizing marijuana use in favor of fines and treatment was put back until next Sunday.

Although the recreational use of cannabis is currently illegal in the Jewish state, for the past 10 years its therapeutic use has not only been permitted but encouraged.

In 2015, doctors prescribed the herb to about 25,000 patients suffering from cancer, epilepsy, post-traumatic stress and degenerative diseases.

Last month, Public Security Minister Gilad Erdan announced his support for decriminalizing recreational use.

Shaked has reportedly indicated she will support it.

Ministers endorse bill to export medicinal cannabis

sabato 18 febbraio 2017

Largest U.S. Banks Host Accounts for Marijuana Businesses, Says American Banker


Jan 31, 2017, 08:30 ET

CORAL SPRINGS, Florida, January 31, 2017 /PRNewswire/ --

A recent study[1] commissioned by industry journal American Banker reveals that the nation's four largest banks have opened accounts for pot shops and marijuana-related businesses. This is good news for companies like Cannabis Science Inc. (OTC: CBIS), Eco Science Solutions, Inc. (OTC: ESSI), Medical Marijuana, Inc. (OTC: MJNA), Marijuana Company of America Inc. (OTC: MCOA), mCig, Inc. (OTCQB: MCIG) and YiLoLife, Inc. - all of which provide a variety of services or interest to the marijuana community and would benefit from commercial banking services.

Conducted by MRB Monitor, a firm that helps financial institutions identify the risks associated with the marijuana industry, the study examined public records in the state of Massachusetts and found that 34 percent of businesses that filed to operate medical marijuana dispensaries in Massachusetts between June 2015 and September 2016 had one or more accounts at Bank of America, Citigroup, Wells Fargo, or JPMorgan Chase.

If a similar pattern of working with the marijuana industry takes hold in Washington D.C. and the U.S. states that have legalized marijuana, the prospect of financial services for cannabis outfits may not be as dire as it at first appears.

Bank of America seems to have been the most accommodating. Over half of the marijuana businesses included in the survey had accounts at the bank, though it previously told the Statesman Journal[2] that, "As a federally regulated financial institution, we abide by federal law and do not bank marijuana-related businesses."

Guidelines issued by federal authorities in 2014 appeared to have offered financial institutions a legal avenue to provide their services to marijuana-related businesses (MRBs). Back then, the Financial Crimes Enforcement Network (FinCEN), part of the U.S. Treasury Department, provided guidance[3] it said was meant to enhance the availability of financial services for, and the financial transparency of, marijuana-related businesses.

Yet, under the Controlled Substances Act (CSA), it is illegal to manufacture, distribute, or dispense marijuana, and marijuana - like heroin, LSD and ecstasy - remains a Schedule 1 substance under the statute.

In December 2016, U.S. Senator Elizabeth Warren, D-Mass, a member of the Senate Banking Committee, along with nine other senators sent a letter to FinCEN requesting guidance on how banking services might be offered to 'indirect businesses' that provide services to the state-sanctioned marijuana industry.

Hopefully, after nomination season comes to a close, a response to that letter will be forthcoming; there's a lot at stake. As ArcView Market Research wrote, "Cannabis is arguably the fastest growing industry in the world. Regulated marijuana sales in North America totaled $6.9 billion in 2016, a 30 percent increase from 2015. Sales are projected to increase to $21.6 billion by the year 2021 representing a 26 percent compound annual growth rate."

YiLoLife is gearing up to reap this burgeoning marijuana harvest. The company recently offered up to 5 million shares of its Class A common stock, at a price of $3.28 per share, under a Regulation A+ filing. YiLoLife plans to use some $12 million from this share offering in adding capital assets, as well as toward the acquisition and development of cultivation, food processing and distribution facilities. A further $1.5 million will be expended on equipment, furniture and fixtures and $1.0 million will go to improve security. The remaining $1.9 million will be allocated toward bolstering working capital.

Other industry players are also positioning themselves. Cannabis Science (CBIS) is a biotech company that discovers and develops novel cannabinoid-based therapies to those critically in need of new treatments for life threatening and debilitating conditions. Eco Science Solutions, Inc. (ESSI) is a Hawaii-based technology company targeting the multi-billion dollar health and wellness industry.

Marijuana Company of America (MCOA) is a marketing and distribution company that plans to deliver all the benefits of cannabis by providing a wide range of services for cannabis businesses and entrepreneurs. The company focuses on leisure, wellness, health, and beauty-specific cannabis products.

Medical Marijuana, Inc. (MJNA), the first publicly traded cannabis company in the United States, announced this week that its subsidiary HempMeds® Mexico has launched its new website, featuring a fresh interface, educational info, and online services for medical marijuana customers.

And last but not least is mCig (MCIG). Driven by a management team with over 75 years of combined experience, this is a company that provides turnkey, durable, modular, ISO clean, high-yielding cultivation rooms to marijuana growers.


1. American Banker

2. Statesman Journal

3. FinCEN

For more information on YiLo please visit the company's crowd-funding page at

Please read all Disclaimers for FULL Compensation Disclosures and other disclaimers

Yilo Disclosure & DTN Disclaimer

DISCLAIMER: (DTN) is source of content listed above. FN Media Group, LLC (FNM), is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated with DTN expressed in this release by DTN are solely those of DTN and are not shared by and do not reflect in any manner the views or opinions of FNM. DTN & FNM is not liable for any investment decisions by its readers or subscribers. FNM and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNM was not compensated by any public company mentioned herein to disseminate this press release.


This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and DTN & FNM undertakes no obligation to update such statements.

Media Contact:, (954)345-0611

domenica 12 febbraio 2017

Marijuana Advocates Are Celebrating This Small Victory

Bloomberg report revealed President-elect Donald Trump's likely pick for Food and Drug Administration (FDA) commissioner, on Wednesday — and it is giving marijuana legalization advocates a glimmer of hope.

Jim O'Neill — an associate at Peter Thiel's Mithril Capital Management and legalization activist, who served as a founding member of the Coalition for Cannabis Policy Reform — could potentially head the federal agency, which plays a central role in shaping the government's cannabis policy.
"Jim O’Neill, the Thiel associate, hasn’t been officially selected, according to the people, who asked to remain anonymous because the decision process is private, and the Trump team could still go in another direction," Bloomberg reported.
The FDA is responsible for determining the medical value of drugs and conducting scientific research that informs the Drug Enforcement Administration (DEA) drug scheduling decisions. Earlier this year, the FDA concluded that marijuana has a "high potential for abuse" and "no currently accepted medical use in treatment," as reported. That determination led the DEA to maintain its current classification of cannabis as a Schedule 1 drug, the most restrictive category under federal law.
A public records request submitted by ATTN: revealed that FDA leadership has raised questions about the DEA's scheduling system and recommended revising the regulatory framework in order to "encourage appropriate scientific research into the potential therapeutic benefits of marijuana and its constituents."
If O'Neill is nominated and confirmed, the position would presumably allow him to push for these reform measures and order a reevaluation of marijuana's medical value, according to cannabis policy experts.
"If O'Neill were to be confirmed as head of the FDA it would, at the very least, provide a voice of support in favor of marijuana law reform within an administration that is appearing to largely be made up of anti-marijuana appointments," Danielle Keane, communications associate at the National Organization for the Reform of Marijuana Laws (NORML), told ATTN:. But Keane also noted that the FDA "is just one small part of the puzzle when it comes to federal action on marijuana law reform."

The marijuana community has responded to the potential nomination of O'Neill with tepid optimism in light of the fact that Trump has also nominated several anti-legalization cabinet members.

Reform advocates have voiced concern about Trump's Attorney General pick, Sen. Jeff Sessions (R-Al.), due to his staunch anti-legalization position, for example.
"Seeing Jim’s name floated gives us reason for a little optimism in the midst of so many old school drug warriors being tapped for other key posts," Marijuana Majority founder Tom Angell told ATTN:. "I feel confident that if he becomes the next FDA commissioner, we will be in very good position to finally reschedule marijuana."
Mike Liszewski, the director of government affairs at Americans for Safe Access, agreed. He told ATTN: that O'Neill's prospective nomination "could bring about significant changes to medical cannabis policy" and "potentially address the regulations that have prevented medical cannabis research."
"Such reforms could ultimately lead to cannabis being removed from Schedule I of the Controlled Substances Act," Liszewski said. "However, whatever progress on cannabis at FDA under the Trump Administration should not be used as justification for cracking down on state medical cannabis programs, as there are more than 2 million patients who rely on these programs for safe and legal access to their medicine."
That said, O'Neill's prospective appointment as FDA commission has raised some concern among health care experts. He lacks a "strong scientific background" and has "proposed that the FDA only require companies to prove drugs are safe before they are sold — not that they actually work," STAT News reported.
O'Neill has also worked alongside Trump advisor Peter Thiel for "over a decade," according to Bloomberg, serving on the board of a controversial ventures such as the Seasteading Institute, which is designed to establish new societies in the ocean, beyond government reach. Before joining Thiel at Mithril Capital Management, O'Neill worked as the principal associated deputy secretary at the U.S. Department of Health and Human Services under former President George W. Bush. Marijuana Advocates Are Celebrating This Small Victory